A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses

Mohadeseh Hasanpourghadi; Mikhail Novikov; Robert Ambrose; Arezki Chekaoui; Dakota Newman; Zhiquan Xiang; Andrew D. Luber; Sue L. Currie; XiangYang Zhou; Hildegund C. Ertl

doi:10.1172/jci.insight.181067

A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses

Mohadeseh Hasanpourghadi,¹ Mikhail Novikov,¹ Robert Ambrose,¹ Arezki Chekaoui,¹ Dakota Newman,¹ Zhiquan Xiang,¹ Andrew D. Luber,² Sue L. Currie,² XiangYang Zhou,¹ and Hildegund C. Ertl¹

Published September 3, 2024 - More info

View PDF

Abstract

In patients who progress from acute hepatitis B virus (HBV) infection to a chronic HBV (CHB) infection, CD8⁺ T cells fail to eliminate the virus and become impaired. A functional cure of CHB likely requires new and highly functional CD8⁺ T cell responses different from those induced by the infection. Here we report preclinical immunogenicity and efficacy of an HBV therapeutic vaccine that includes herpes simplex virus (HSV) glycoprotein D (gD), a checkpoint modifier of early T cell activation, that enhances, broadens, and prolongs CD8⁺ T cell responses. We developed a therapeutic HBV vaccine based on a chimpanzee adenovirus serotype 6 (AdC6) vector, called AdC6-gDHBV2, that targets conserved and highly immunogenic regions of the viral polymerase (pol) and core antigens fused into HSV gD. The vaccine was tested with, and without gD, in mice for immunogenicity and in an adeno-associated virus (AAV)8-1.3HBV vector model for antiviral efficacy. The vaccine encoding the HBV antigens within gD stimulates potent and broad CD8+ T cell responses. In a surrogate model of HBV infection, a single intramuscular (i.m.) injection of AdC6-gDHBV2 achieved significant and sustained declines of circulating HBV DNA copies (cps) and HBV surface antigen (HBsAg); both inversely correlated with HBV specific CD8⁺ T cell frequencies in spleens and livers. AdC6-gDHBV2 is the first therapeutic vaccine to show significant reductions in levels of HBV genome copies and HBsAg when used alone, even when vaccination was delayed for months from infection.

A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses

Mohadeseh Hasanpourghadi,¹ Mikhail Novikov,¹ Robert Ambrose,¹ Arezki Chekaoui,¹ Dakota Newman,¹ Zhiquan Xiang,¹ Andrew D. Luber,² Sue L. Currie,² XiangYang Zhou,¹ and Hildegund C. Ertl¹

Article tools

Metrics

Go to

A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses

Mohadeseh Hasanpourghadi,1 Mikhail Novikov,1 Robert Ambrose,1 Arezki Chekaoui,1 Dakota Newman,1 Zhiquan Xiang,1 Andrew D. Luber,2 Sue L. Currie,2 XiangYang Zhou,1 and Hildegund C. Ertl1

Article tools

Metrics

Go to

Sign up for email alerts

Mohadeseh Hasanpourghadi,¹ Mikhail Novikov,¹ Robert Ambrose,¹ Arezki Chekaoui,¹ Dakota Newman,¹ Zhiquan Xiang,¹ Andrew D. Luber,² Sue L. Currie,² XiangYang Zhou,¹ and Hildegund C. Ertl¹